🟢 GH Research is trading 5% up in pre-market after GH001 Phase 3 readiness update

GH Research is trading 4.93% up now at $31.76 after its August 6, 2026, earnings release highlighted Phase 3 readiness for GH001.

• FDA responses indicated its CMC and device plans appear Phase 3 ready, with device and clinical pharmacology milestones completed.
• GH Research continues targeting global pivotal-trial initiation in 2026; cash and marketable securities totaled $362.7 million at June 30.
• The release did not explicitly attribute the movement to the announcement; broader risk-on technology sentiment may also support shares.